Lavanya Moses Suneetha
Research Subjects
Lavanya Moses Suneetha has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Aparna Sykam
Nireekshana-ACET/CODEWEL, Hyderabad, Telangana 500029, India; Centre for Biotechnology, Acharya Nagarjuna University, Nagarjuna Nagar, Guntur, Andhra Pradesh 522510, India
5 shared publicationsSujai Suneetha
CODEWEL Nireekshana ACET, Narayanaguda, Hyderabad -500029, Telangana, India
5 shared publicationsA.K. Meena
Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana 500082, India
3 shared publicationsSandeep P. Tenali
Nireekshana-ACET/CODEWEL, Hyderabad, Telangana 500029, India
3 shared publicationsV.R. Gutlapalli
Nireekshana-ACET/CODEWEL, Hyderabad, Telangana 500029, India; Centre for Biotechnology, Acharya Nagarjuna University, Nagarjuna Nagar, Guntur, Andhra Pradesh 522510, India
3 shared publicationsD.V.S. Pratap
Dermatology Department, Osmania General Hospital, Hyderabad, Telangana 500058, India
2 shared publications
Latest Publications
- Open Access
- 31 May 2018
- Published by Biomedical Informatics in Bioinformation
- Vol. 14 (05) , 194-200
Insights from the sequence similarity of Zika virus proteins with the Human nerve proteins
Massive peptide sharing between the Zika virus polyprotein and host tissue proteins could elicit significant host-pathogen interactions and cross-reactions leading to autoimmune diseases. This study found similarities in the Zika V proteins and human nerve tissue proteins. 63 human nerve proteins were screened for similarities with the Zika V of which Neuromodulin, Nestin, Galanin, Bombesin, Calcium-binding protein were found to have similarities to the Zika V poly protein C at different sequence regions. These sequence similarities could be significant in regulating pathogenic interactions/autoimmunity, as Polyprotein C is known to be a virulent factor.
- 31 May 2018
- Published by Biomedical Informatics in Bioinformation
- Vol. 14 (05) , 194-200
Open AccessInsights from the sequence similarity of Zika virus proteins with the Human nerve proteins
Massive peptide sharing between the Zika virus polyprotein and host tissue proteins could elicit significant host-pathogen interactions and cross-reactions leading to autoimmune diseases. This study found similarities in the Zika V proteins and human nerve tissue proteins. 63 human nerve proteins were screened for similarities with the Zika V of which Neuromodulin, Nestin, Galanin, Bombesin, Calcium-binding protein were found to have similarities to the Zika V poly protein C at different sequence regions. These sequence similarities could be significant in regulating pathogenic interactions/autoimmunity, as Polyprotein C is known to be a virulent factor.
- Open Access
- 21 February 2018
- Published by IntechOpen
Bioinformatics as a Tool to Identify Infectious Disease Pathogen Peptide Sequences as Targets for Antibody Engineering
Bioinformatics is an interdisciplinary field of information technology for understanding biological data from genome to protein. It includes a combination of fields of science, computer science, statistics, mathematics, and engineering to analyze, interpret and derive biological data. This chapter describes how to use Bioinformatics to identify pathogen virulence factor peptide sequence similarities in human nerve tissue proteins and for evaluation as antibody engineering target peptides.
- 21 February 2018
- Published by IntechOpen
Open AccessBioinformatics as a Tool to Identify Infectious Disease Pathogen Peptide Sequences as Targets for Antibody Engineering
Bioinformatics is an interdisciplinary field of information technology for understanding biological data from genome to protein. It includes a combination of fields of science, computer science, statistics, mathematics, and engineering to analyze, interpret and derive biological data. This chapter describes how to use Bioinformatics to identify pathogen virulence factor peptide sequence similarities in human nerve tissue proteins and for evaluation as antibody engineering target peptides.
- 1 August 2017
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 42, 204-208
Anticeramide antibody and butyrylcholinesterase in peripheral neuropathies
- 1 August 2017
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 42, 204-208
Anticeramide antibody and butyrylcholinesterase in peripheral neuropathies
- 1 December 2016
- Published by Elsevier in Human Immunology
- Vol. 77 (12) , 1264-1270
High levels of plasma interferon gamma and +874T/A gene polymorphism is associated with HIV-TB co-infection
- 1 December 2016
- Published by Elsevier in Human Immunology
- Vol. 77 (12) , 1264-1270
High levels of plasma interferon gamma and +874T/A gene polymorphism is associated with HIV-TB co-infection
- 1 September 2016
- Published by Elsevier in Medical Hypotheses
- Vol. 94, 112-117
Phenotypic characterization of a pair of molecules in tissues confer to classical Mendelian or non Mendelian ratios
- 1 September 2016
- Published by Elsevier in Medical Hypotheses
- Vol. 94, 112-117
Phenotypic characterization of a pair of molecules in tissues confer to classical Mendelian or non Mendelian ratios
- Open Access
- 31 December 2015
- Published by Biomedical Informatics in Bioinformation
- Vol. 11 (12) , 517-524
Insights from the predicted epitope similarity between Mycobacterium tuberculosis virulent factors and its human homologs
Mycobacterium tuberculosis is known to be associated with several autoimmune diseases such as systemic lupus erythematous, rheumatoid arthritis and multiple sclerosis. This is attributed to sequence similarity between virulent factors and human proteins. Therefore, it is of interest to identify such regions in the virulent factors to assess potential autoimmune related information. M. tb specific virulent factors were downloaded from the VFDB database and its human homologs were identified using the sequence comparison search tool BLASTP. Both virulent proteins and their corresponding human homologs were further scanned for epitopes (B cell and HLA class I and II allele specific) using prediction programs (BCPRED and NETMHC). Data shows the presence of matching 22 B-cell, 79 HLA class II and 16 HLA class I specific predicted epitopes in these virulent factors having human homologs. A known peptide (HAFYLQYKNVKVDFA) associated with autoimmune atopic dermatitis is shown in the superoxide dismutase homolog structures of the bacterium (PDB ID: 1IDS) and human (PDB ID: 2QKC). This data provides insight into the understanding of infection-associated auto-immunity
- 31 December 2015
- Published by Biomedical Informatics in Bioinformation
- Vol. 11 (12) , 517-524
Open AccessInsights from the predicted epitope similarity between Mycobacterium tuberculosis virulent factors and its human homologs
Mycobacterium tuberculosis is known to be associated with several autoimmune diseases such as systemic lupus erythematous, rheumatoid arthritis and multiple sclerosis. This is attributed to sequence similarity between virulent factors and human proteins. Therefore, it is of interest to identify such regions in the virulent factors to assess potential autoimmune related information. M. tb specific virulent factors were downloaded from the VFDB database and its human homologs were identified using the sequence comparison search tool BLASTP. Both virulent proteins and their corresponding human homologs were further scanned for epitopes (B cell and HLA class I and II allele specific) using prediction programs (BCPRED and NETMHC). Data shows the presence of matching 22 B-cell, 79 HLA class II and 16 HLA class I specific predicted epitopes in these virulent factors having human homologs. A known peptide (HAFYLQYKNVKVDFA) associated with autoimmune atopic dermatitis is shown in the superoxide dismutase homolog structures of the bacterium (PDB ID: 1IDS) and human (PDB ID: 2QKC). This data provides insight into the understanding of infection-associated auto-immunity
- Open Access
- 28 July 2014
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 13 (1) , 119
Serological responses to prednisolone treatment in leprosy reactions: study of TNF-α, antibodies to phenolic glycolipid-1, lipoarabinomanan, ceramide and S100-B
Corticosteroids have been extensively used in the treatment of immunological reactions and neuritis in leprosy. The present study evaluates the serological response to steroid treatment in leprosy reactions and neuritis. Seven serological markers [TNF-α, antibodies to Phenolic glycolipid-1 (PGL-1 IgM and IgG), Lipoarabinomannan (LAM IgG1 and IgG3), C2-Ceramide and S100 B] were analyzed longitudinally in 72 leprosy patients before, during and after the reaction. At the onset of reaction these patients received a standard course of prednisolone. The levels of the above markers were measured by Enzyme linked immunosorbent assay (ELISA) and compared with the individuals own value in the month prior to the reaction and presented as percentage increase. One month before the reaction individuals showed a varying increase in the level of different markers such as TNF-α (53%) and antibodies to Ceramide (53%), followed by to PGL-1 (51%), S100B (50%) and LAM (26%). The increase was significantly associated with clinical finding of nerve pain, tenderness and new nerve function impairment. After one month prednisolone therapy, there was a fall in the levels [TNF-α (60%), C2-Ceramide (54%), S100B (67%), PGL-1(47%) and LAM (52%)] with each marker responding differently to steroid. Reactions in leprosy are inflammatory processes wherein a rise in set of serological markers can be detected a month before the clinical onset of reaction, some of which remain elevated during their action and steroid treatment induces a variable fall in the levels, and this forms the basis for a variable individual response to steroid therapy.
- 28 July 2014
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 13 (1) , 119
Open AccessSerological responses to prednisolone treatment in leprosy reactions: study of TNF-α, antibodies to phenolic glycolipid-1, lipoarabinomanan, ceramide and S100-B
Corticosteroids have been extensively used in the treatment of immunological reactions and neuritis in leprosy. The present study evaluates the serological response to steroid treatment in leprosy reactions and neuritis. Seven serological markers [TNF-α, antibodies to Phenolic glycolipid-1 (PGL-1 IgM and IgG), Lipoarabinomannan (LAM IgG1 and IgG3), C2-Ceramide and S100 B] were analyzed longitudinally in 72 leprosy patients before, during and after the reaction. At the onset of reaction these patients received a standard course of prednisolone. The levels of the above markers were measured by Enzyme linked immunosorbent assay (ELISA) and compared with the individuals own value in the month prior to the reaction and presented as percentage increase. One month before the reaction individuals showed a varying increase in the level of different markers such as TNF-α (53%) and antibodies to Ceramide (53%), followed by to PGL-1 (51%), S100B (50%) and LAM (26%). The increase was significantly associated with clinical finding of nerve pain, tenderness and new nerve function impairment. After one month prednisolone therapy, there was a fall in the levels [TNF-α (60%), C2-Ceramide (54%), S100B (67%), PGL-1(47%) and LAM (52%)] with each marker responding differently to steroid. Reactions in leprosy are inflammatory processes wherein a rise in set of serological markers can be detected a month before the clinical onset of reaction, some of which remain elevated during their action and steroid treatment induces a variable fall in the levels, and this forms the basis for a variable individual response to steroid therapy.
- 1 June 2013
- Published by Lepra in Leprosy Review
- Vol. 84 (2) , 161-165
Use of high resolution ultrasonography as an additional tool in the diagnosis of primary neuritic leprosy: a case report
- 1 June 2013
- Published by Lepra in Leprosy Review
- Vol. 84 (2) , 161-165
Use of high resolution ultrasonography as an additional tool in the diagnosis of primary neuritic leprosy: a case report
- 1 September 2011
- Published by Lepra in Leprosy Review
- Vol. 82 (3) , 244-252
Changes in the size and number of skin lesions in PB leprosy on treatment and follow-up
Background: The increase in size of existing skin lesions and appearance of new skin lesions are considered important signs of clinical activity both in untreated and treated leprosy. To confirm such activity, the number and size of lesions need to be recorded methodically prior to therapy and on follow-up, especially in PB leprosy where clinical signs alone define the reactivation of the disease. However, no systematic follow-up studies are available on changes in size and number of skin lesions in PB leprosy before and after therapy. Objectives: To measure changes in the number and size of skin lesions in PB leprosy patients before starting MDT PB and after 18 months follow-up in order to evaluate their relevance in assessing clinical improvement and identifying possible relapses. Design: In 32 untreated leprosy patients with 1–5 skin lesions, the number of skin lesions were recorded on body charts and their size measured using a grid chart method to arrive at total area of involvement in each patient prior to starting MDT PB and after 18 months. Skin smears and skin biopsies were performed at entry and follow-up to assist the clinical evaluation. Results: Twenty three patients had single skin lesion (SSL), followed by three each with two and three skin lesions respectively, two with four and one with five skin lesions. The area of involvement ranged from six to 1686 sq cm. Few patients with SSL had higher areas of involvement than those who had multiple skin lesions. On follow-up at 18 months, in 14 (44%) patients skin lesions were not measurable, while in 18 (56%) they were measurable, with eight (25%) patients showing no change, three (9%) showing decrease and seven (22%) showing increase in area of involvement. Of the seven patients showing increase, in three it was due to the spread of existing skin lesions alone, in one it was due to a new skin lesion alone and in three due to the spread of existing skin lesions and the appearance of new skin lesions. New skin lesions were multiple (>3) in two patients. T1R was observed in three out of four patients with new skin lesions, and this was persistent at 18 months in one patient. When histopathology at the entry and 18 month follow-up was compared, in one patient with persistent T1R with appearance of multiple new skin lesions, there was increase in GF from 10 to 40% with histological features of T1R and a BI of granuloma of 1+. Conclusions: In 32 treated patients of PB leprosy on 18 month follow-up for changes in size and number of skin lesions, of six patients showing increase in area of involvement of existing skin lesions, 3 (50%) developed new skin lesions, indicating persistent disease activity. The new lesions which were associated with T1R increased the total number of skin lesions to >5 in two of these patients requiring a change of drug regimen from PB to MB MDT, with one of them fulfilling clinical and histopathological criteria for relapse of leprosy. Hence, although new lesions are known to occur as part of T1R in PB patients, they are events of great significance which need to be assessed in a methodical manner for their influence on classification and therapy of leprosy.
- 1 September 2011
- Published by Lepra in Leprosy Review
- Vol. 82 (3) , 244-252
Changes in the size and number of skin lesions in PB leprosy on treatment and follow-up
Background: The increase in size of existing skin lesions and appearance of new skin lesions are considered important signs of clinical activity both in untreated and treated leprosy. To confirm such activity, the number and size of lesions need to be recorded methodically prior to therapy and on follow-up, especially in PB leprosy where clinical signs alone define the reactivation of the disease. However, no systematic follow-up studies are available on changes in size and number of skin lesions in PB leprosy before and after therapy. Objectives: To measure changes in the number and size of skin lesions in PB leprosy patients before starting MDT PB and after 18 months follow-up in order to evaluate their relevance in assessing clinical improvement and identifying possible relapses. Design: In 32 untreated leprosy patients with 1–5 skin lesions, the number of skin lesions were recorded on body charts and their size measured using a grid chart method to arrive at total area of involvement in each patient prior to starting MDT PB and after 18 months. Skin smears and skin biopsies were performed at entry and follow-up to assist the clinical evaluation. Results: Twenty three patients had single skin lesion (SSL), followed by three each with two and three skin lesions respectively, two with four and one with five skin lesions. The area of involvement ranged from six to 1686 sq cm. Few patients with SSL had higher areas of involvement than those who had multiple skin lesions. On follow-up at 18 months, in 14 (44%) patients skin lesions were not measurable, while in 18 (56%) they were measurable, with eight (25%) patients showing no change, three (9%) showing decrease and seven (22%) showing increase in area of involvement. Of the seven patients showing increase, in three it was due to the spread of existing skin lesions alone, in one it was due to a new skin lesion alone and in three due to the spread of existing skin lesions and the appearance of new skin lesions. New skin lesions were multiple (>3) in two patients. T1R was observed in three out of four patients with new skin lesions, and this was persistent at 18 months in one patient. When histopathology at the entry and 18 month follow-up was compared, in one patient with persistent T1R with appearance of multiple new skin lesions, there was increase in GF from 10 to 40% with histological features of T1R and a BI of granuloma of 1+. Conclusions: In 32 treated patients of PB leprosy on 18 month follow-up for changes in size and number of skin lesions, of six patients showing increase in area of involvement of existing skin lesions, 3 (50%) developed new skin lesions, indicating persistent disease activity. The new lesions which were associated with T1R increased the total number of skin lesions to >5 in two of these patients requiring a change of drug regimen from PB to MB MDT, with one of them fulfilling clinical and histopathological criteria for relapse of leprosy. Hence, although new lesions are known to occur as part of T1R in PB patients, they are events of great significance which need to be assessed in a methodical manner for their influence on classification and therapy of leprosy.